Chinese Drug Official Sentenced to Four Years in Prison for Taking Bribes (China)
This article was originally published in PharmAsia News
Zheng Shangjin, previously chief of Zhejiang Provincial Food and Drug Bureau, has been convicted of taking bribes and sentenced to four years in prison by the Yantian District Court in Shenzhen City, south China's Guangdong Province. Shangjin once arranged a meeting between Tang Xudong, president of Kangliyuan Group, his brother Tang Xiaodong, and Zheng Xiaoyu, former director of China's State Food and Drug Administration (SFDA), when the former SFDA chief was in Zhejiang to attend a local fair. He also used his influence to obtain other benefits for the company, according to the court, which also said that as a government official, Shangjin abused his power and accepted bribes totaling 680,000 yuan from the Tang brothers on two separate occasions. (Click here for more - May Require Free Registration
You may also be interested in...
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.
FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.